Literature DB >> 14702116

Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis.

Adam Grundhoff1, Don Ganem.   

Abstract

Kaposi sarcoma-associated (KS-associated) herpesvirus (KSHV) infection is linked to the development of both KS and several lymphoproliferative diseases. In all cases, the resulting tumor cells predominantly display latent viral infection. KS tumorigenesis requires ongoing lytic viral replication as well, however, for reasons that are unclear but have been suggested to involve the production of angiogenic or mitogenic factors by lytically infected cells. Here we demonstrate that proliferating cells infected with KSHV in vitro display a marked propensity to segregate latent viral genomes, with only a variable but small subpopulation being capable of stable episome maintenance. Stable maintenance is not due to the enhanced production of viral or host trans-acting factors, but is associated with cis-acting, epigenetic changes in the viral chromosome. These results indicate that acquisition of stable KSHV latency is a multistep process that proceeds with varying degrees of efficiency in different cell types. They also suggest an additional role for lytic replication in sustaining KS tumorigenesis: namely, the recruitment of new cells to latency to replace those that have segregated the viral episome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14702116      PMCID: PMC300762          DOI: 10.1172/JCI17803

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

1.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.

Authors:  D F Martin; B D Kuppermann; R A Wolitz; A G Palestine; H Li; C A Robinson
Journal:  N Engl J Med       Date:  1999-04-08       Impact factor: 91.245

2.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

3.  The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant.

Authors:  S Sozzani; W Luini; G Bianchi; P Allavena; T N Wells; M Napolitano; G Bernardini; A Vecchi; D D'Ambrosio; D Mazzeo; F Sinigaglia; A Santoni; E Maggi; S Romagnani; A Mantovani
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

4.  Cyclin encoded by KS herpesvirus.

Authors:  Y Chang; P S Moore; S J Talbot; C H Boshoff; T Zarkowska; H Paterson; R A Weiss; S Mittnacht
Journal:  Nature       Date:  1996-08-01       Impact factor: 49.962

5.  Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen.

Authors:  M E Ballestas; P A Chatis; K M Kaye
Journal:  Science       Date:  1999-04-23       Impact factor: 47.728

6.  Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis.

Authors:  J R Kirshner; K Staskus; A Haase; M Lagunoff; D Ganem
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Absence of human herpesvirus 8 DNA sequences in neoplastic Kaposi's sarcoma cell lines.

Authors:  L Flamand; R A Zeman; J L Bryant; Y Lunardi-Iskandar; R C Gallo
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-10-01

8.  Human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) DNA in Kaposi's sarcoma lesions, AIDS Kaposi's sarcoma cell lines, endothelial Kaposi's sarcoma simulators, and the skin of immunosuppressed patients.

Authors:  M Dictor; E Rambech; D Way; M Witte; N Bendsöe
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

Review 9.  Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents.

Authors:  B Ensoli; M Stürzl
Journal:  Cytokine Growth Factor Rev       Date:  1998-03       Impact factor: 7.638

10.  Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma.

Authors:  N Dupin; C Fisher; P Kellam; S Ariad; M Tulliez; N Franck; E van Marck; D Salmon; I Gorin; J P Escande; R A Weiss; K Alitalo; C Boshoff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

View more
  206 in total

1.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

2.  New viruses shake old paradigms.

Authors:  Chen-Yu Wang; Bill Sugden
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 3.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

Review 4.  Kaposi's sarcoma and its associated herpesvirus.

Authors:  Enrique A Mesri; Ethel Cesarman; Chris Boshoff
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

5.  Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2.

Authors:  Meilan He; Wei Zhang; Thomas Bakken; Melissa Schutten; Zsolt Toth; Jae U Jung; Parkash Gill; Mark Cannon; Shou-Jiang Gao
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

6.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

7.  Envelope glycoprotein gB of Kaposi's sarcoma-associated herpesvirus is essential for egress from infected cells.

Authors:  Harinivas H Krishnan; Neelam Sharma-Walia; Ling Zeng; Shou-Jiang Gao; Bala Chandran
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  The KSHV viral interleukin-6 is not essential for latency or lytic replication in BJAB cells.

Authors:  Lei Chen; Michael Lagunoff
Journal:  Virology       Date:  2006-10-30       Impact factor: 3.616

9.  Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.

Authors:  Huong Q Nguyen; Amalia S Magaret; Mari M Kitahata; Stephen E Van Rompaey; Anna Wald; Corey Casper
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

10.  Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif.

Authors:  Lai-Yee Wong; Gerald A Matchett; Angus C Wilson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.